On August 12, 2026, the clinical trial registry updated the status of NCT04126070 to active, not recruiting. The trial is titled "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors." It is registered as a Phase 2 study. Androgen deprivation therapy, which can include goserelin, is part of the treatment regimen under investigation in this trial. The current status indicates that participant enrollment has closed but the study is continuing in later stages, such as follow up or data analysis. No results have been posted as part of this update. The trial record does not specify additional details regarding outcomes at this time. This update reflects only the trial's operational status as recorded in the registry entry dated August 12, 2026. Readers seeking further context on goserelin, including its approved uses and general background, can consult the compound overview.
Goserelin-Linked Trial NCT04126070 Now Active, Not Recruiting
See the full goserelin overview
Source: https://clinicaltrials.gov/study/NCT04126070